BSH 2022 | Highlights from BSH: genetic profiling in CLL
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares some highlights from BSH 2022, briefly discussing a presentation which focused on the genetic profiling of chronic lymphocytic leukemia (CLL), and the importance of investigating genomic aberrations in this disease. Dr Eichhorst highlights the complexity of CLL, and the need to further evaluate genomic data to improve and personalize treatment approaches for patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
I receive honoraria for presentations and advisory board from several different pharmaceutical companies involved in targeted agents in CLL (Abbvie, BeiGene, BMS, Gilead, Janssen, MSD, Roche).
